RankingsLogo

Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. is a Humankind 100 company whose ranking is based on its Humankind Value, a proprietary metric that provides an estimate of the overall dollar amount a company creates for investors, consumers, employees, and society at large.

Regeneron Pharmaceuticals, Inc. is a pharmaceutical and biotechnology company that focuses on researching and developing treatments. Its products treat metabolic and heart diseases, infectious diseases, inflammation, cancers, and more.

Ticker: REGN

Humankind Value: $173.1 B

Revenue: $12.0 B

Market Cap: $105.9 B

Badge100_2024
Positive and negative impacts of companies graphic.

(All values are in US Dollars, where M=Million, B=Billion, T=Trillion.)

Regeneron Pharmaceuticals, Inc. generates positive Humankind Value on balance. The greatest contributors to this positive outcome are Healthcare R&D ($133.7 B), Pharmaceuticals ($35.1 B), and Economic Value ($3.9 B). This company’s Humankind Value associated with Healthcare R&D and Pharmaceuticals is linked to an estimate of 3,200,000 additional years lived by people worldwide. Downsides for this company are associated with Greenhouse Gases (-$777.2 M) and Air Pollution (-$98.5 M). Healthcare R&D, Pharmaceuticals, Economic Value, Greenhouse Gases, and Air Pollution impacts are all attached to this company as a result of its direct business activities.

How the Humankind Value Methodology Drives the Rankings

We take a quantitative, data-driven approach to estimating the economic impact that companies have on investors, customers, employees, and society at large, rolling social responsibility into a single dollar value that we use to represent what a company is contributing to humanity. As far as we can tell, we're the first ones doing it this way.

LEARN MORE ABOUT OUR RESEARCH
How Methodology Drives the Rankings